🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 15 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
05/02/2024 14,80 15,40 14,76 15,22 +1,74% 4,32% 677.500
02/02/2024 15,55 15,72 14,62 14,96 -5,62% 7,07% 898.700
01/02/2024 15,92 16,41 15,50 15,85 +4,69% 5,68% 1.428.200
31/01/2024 15,70 16,10 15,12 15,14 -3,69% 6,24% 1.290.800
30/01/2024 16,11 16,77 15,17 15,72 +2,75% 9,91% 2.115.200
29/01/2024 15,10 15,41 14,80 15,30 +1,12% 4,04% 610.700
26/01/2024 15,45 15,67 14,97 15,13 -0,85% 4,52% 289.700
25/01/2024 15,36 15,71 15,05 15,26 +0,07% 4,26% 579.500
24/01/2024 15,58 15,58 15,02 15,25 -1,23% 3,59% 608.900
23/01/2024 15,41 15,72 15,05 15,44 +2,18% 4,35% 1.019.600
22/01/2024 15,37 15,86 14,84 15,11 -1,50% 6,67% 829.500
19/01/2024 16,41 16,41 15,20 15,34 -6,29% 7,37% 1.869.000
18/01/2024 17,09 17,42 16,27 16,37 -3,71% 6,73% 799.300
17/01/2024 16,82 17,03 16,54 17,00 +0,59% 2,88% 499.800
16/01/2024 17,19 17,19 16,33 16,90 -3,48% 5,00% 562.900
12/01/2024 17,45 18,05 17,43 17,51 +0,92% 3,55% 439.400
11/01/2024 17,57 17,70 17,29 17,35 -3,02% 2,33% 568.500
10/01/2024 18,56 18,92 17,58 17,89 -4,02% 7,22% 432.300
09/01/2024 18,60 19,00 18,39 18,64 -0,75% 3,28% 590.900
08/01/2024 17,73 18,82 17,32 18,78 +5,92% 8,49% 955.600
05/01/2024 18,61 18,90 17,70 17,73 -6,68% 6,45% 724.700
04/01/2024 19,73 20,10 18,98 19,00 -3,70% 5,65% 921.000
03/01/2024 19,49 19,97 19,12 19,73 +0,25% 4,37% 684.300
02/01/2024 19,03 20,27 18,83 19,68 +3,04% 7,57% 623.600
29/12/2023 19,62 19,62 19,02 19,10 -2,70% 3,06% 503.800
28/12/2023 18,90 19,67 18,90 19,63 +4,08% 4,07% 835.700
27/12/2023 18,42 18,87 18,18 18,86 +2,39% 3,75% 646.000
26/12/2023 18,40 18,74 18,22 18,42 +1,49% 2,83% 454.700
22/12/2023 17,81 18,34 17,38 18,15 +3,54% 5,39% 655.200
21/12/2023 17,34 17,76 17,20 17,53 +2,57% 3,23% 395.900